ACAD Key Stats
|Revenue (Quarterly YoY Growth)||-93.10%|
|EPS Diluted (TTM)||-0.4222|
|EPS Diluted (Quarterly YoY Growth)|
|Net Income (TTM)||-32.71M|
|Gross Profit Margin (Quarterly)|
|Profit Margin (Quarterly)||-4456%|
|Dividend Yield (TTM)||0%|
|Payout Ratio (TTM) Pro||Go Pro|
- Why Acadia Is A Promising Investment Seeking Alpha Dec 4
- ACADIA Pharmaceuticals Inc. (ACAD): Today's Featured Drugs Winner The Street Dec 4
- ACADIA Pharmaceuticals' CEO Presents at 25th Annual Piper Jaffray Healthcare Conference (Transcript) Seeking Alpha Dec 3
- ACADIA Pharmaceuticals (ACAD) Highlighted As Today's Perilous Reversal Stock The Street Dec 3
- ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences noodls Nov 26
- 2 Biotech Stocks With Strong Buyout Potential Wall St. Cheat Sheet Nov 25
- The Best- And Worst-Performing Biotech Stocks, Nov. 15 to Nov. 22 Forbes Nov 23
- 3 Drugmakers on the Move Fool Nov 22
- Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan Nov 22
- [video] Biotech index hits an all-time high CNBC Nov 21
ACAD Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). ACADIA Pharmaceuticals is up 422.1% over the last year vs S&P 500 Total Return up 30.90%, Celldex Therapeutics up 345.3%, and Ariad Pharmaceuticals down 81.29%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for ACAD
Pro Report PDF for ACAD
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download ACAD Pro Report PDF
Pro Strategies Featuring ACAD
Did ACADIA Pharmaceuticals make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
ACADIA Pharmaceuticals Inc. is in the business of development and commercialization of small molecule drugs for the treatment of central nervous system disorders.